CloneID: P17
Heavy Chain modification: Fc Silent™
Antigen Long Description: The original antibody was generated in the screening studies by using recombinant RBD of SARS-CoV-2 as a target against a fully human naive antibody library.
Buffer Composition: PBS with 0.02% Proclin 300.
Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7
Uniprot Accession No.: P0DTC2
Specificity Statement: The antibody binds the Spike protein of the SARS-CoV-2. The antibody does not crossreact with SARS-CoV RBD.
Application Notes (Clone): The specificity of the antibody was confirmed by ELISA analysis (EC50 = 29 pM). Surface plasmon resonance (SPR) assays demonstrated that the antibody bound to SARS-CoV-2 RBD with a high affinity of 96 pM. Immunofluorescence staining showed that the antibody prevented SARS-CoV-2 infection in a dosedependent manner in Vero cells. Pseudovirus neutralization assay (PSV) in Huh7 cells and standard 50% plaque reduction neutralization tests (PRNT) in Vero cells, both showed that the antibody exhibited stronger neutralizing activity with IC50 and PRNT50 values of 165 and 195 pM, respectively. The antibody conferred effective protection in animal models. The structure of the Fab fragment and a prefusion stabilized SARSCoV-2 S ectodomain trimer was characterized using single-particle cryo-EM. The antibody was employed together with H014 to develop a therapeutic antibody cocktail against SARS-CoV-2 with neutralizing properties (Yao et al., 2021; PMID: 33262452).
Deutsch
English
